On the one hand, as an immunogenic cell death (ICD) inducer, OXA produces many double-stranded DNA (dsDNA) cross-links, providing enough tumor-specific antigen or tumor-associated antigen (TAA) for STING agonist-induced anti-tumor immunity, thus enabling the entire tumor to be converted into a vaccine [62], which will greatly increase the therapeutic effect. This evidence concerns the gene STING1 and neoplasm.